Skip to main content

Table 2 Statin medication use characteristics among uveitis cases and control subjects

From: Statin use and ocular inflammatory disease risk

 

Uveitis cases

Control subjects

OR (95% CI)

OR (95% CI) a

p value

Number of subjects

92

920

   

Statin use

 No

84 (91.3)

819 (89.0)

1.00 (reference)

1

 

 Yes

8 (8.7)

101 (11.0)

0.79 (0.38 to 1.63)

0.50 (0.20 to 1.23)

0.13

 Current use

4 (4.4)

53 (5.8)

0.76 (0.28 to 2.06)

0.46 (0.15 to 1.46)

0.19

 Past use

4 (4.4)

48 (5.2)

0.83 (0.30 to 2.26)

0.54 (0.18 to 1.67)

0.29

Duration of use (month)

 No use

84 (91.3)

819 (89.0)

1.00 (reference)

1

 

 <12

5 (5.4)

44 (4.8)

1.10 (0.45 to 2.70)

0.74 (0.27 to 2.07)

0.57

 12 to 23

2 (2.2)

23 (2.5)

0.86 (0.21 to 3.50)

0.45 (0.10 to 2.01)

0.29

 >23

1 (1.1)

34 (3.7)

0.31 (0.04 to 2.21)

0.19 (0.02 to 1.52)

0.12

  1. Values are expressed as number (percentage) of individuals unless otherwise indicated. Analyses are for OID versus no OID. OID, ocular inflammatory disease; OR, odds ratio. aAdjusted for diabetes, lipid metabolism disorders, hypertension, cardiovascular disease, cerebrovascular disease, and arterial disease.